Navigation Links
London's Royal Brompton Hospital Opens New Electrophysiology Lab With State of the Art Magnetic Technology to Treat Arrhythmias
Date:6/24/2008

Installation of Stereotaxis Niobe(R) and Odyssey(TM) Systems Further Royal Brompton and Harefield NHS Trust's Leadership Role in the Treatment of

Complex Heart Conditions

ST. LOUIS, June 24 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS) announced that British Prime Minister Gordon Brown presided today over a ceremony unveiling the new state of the art electrophysiology lab at Royal Brompton Hospital in London. The new lab features Stereotaxis Niobe Magnetic Navigation and Odyssey Network systems, which in combination can provide unsurpassed safety, efficiency and clinical efficacy for the entire range of arrhythmia procedures performed in all four chambers of the heart. The new lab will be led by Dr. Sabine Ernst, Consultant Electrophysiologist and a pioneer in the application of magnetic navigation technology to electrophysiology.

"Through this installation we are continuing Royal Brompton and Harefield's long tradition of bringing the best possible medical care to our diverse patient population," said Dr. Ernst. "The Stereotaxis technology has emerged as the preferred therapeutic choice to treat a wide variety of arrhythmias. Magnetic navigation, combined with a very gentle catheter provides us with more precise catheter placement and allows us to access areas of the heart that may have been hard to reach utilizing other technologies or manual manipulation. As a result, patients with difficult to treat arrhythmias may find a successful resolution to their condition through a procedure performed on our new system."

"The installation of the combined Stereotaxis Niobe and Odyssey systems at the prestigious Royal Brompton Hospital represents another important milestone in establishing our technology in the leading hospitals of the world," said Bevil Hogg, CEO of Stereotaxis. "We believe our Stereotaxis Niobe system has demonstrated a peerless record of clinical safety, efficacy, and efficiency over more than 15,000 procedures, and now our Odyssey networked information management system is making it possible for physicians to better manage clinical workflows, archive procedures and is expected to play a critical role in the world wide dissemination of best practices."

Royal Brompton and Harefield NHS Trust is a national and international leader in the treatment of complex heart and lung conditions and is recognized for its contribution to cardiac research and advanced medicine. The hospital's adult congenital heart disease unit was the first of its kind in Europe and remains the largest. Royal Brompton acquired the United Kingdom's first dedicated cardiac CT scanner in 2005, and has the largest cardiac magnetic resonance center in the world.

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe and Canada.

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company's products in the marketplace, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.


'/>"/>
SOURCE Stereotaxis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. VNUS Update and Correction to 2008 Royalty Revenues
2. Unilens Vision Reports Increased Royalty Income
3. Unilens Vision Reports 70% Increase in Second Quarter Earnings on Higher Sales and Record Royalty Income
4. EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to GlaxoSmithKline for up to $44 Million Plus Royalties
5. His Royal Highness The Duke of York Helps Launch UK-Based Pharmaceutical Company, ProStrakan, in the United States
6. Royal Philips Electronics to Acquire Respironics for USD $66.00 Per Share
7. Royalty Pharma Acquires a Portion of Northwestern Universitys Royalty Interest in Lyrica(R) for $700 Million
8. Unilens Vision Reports Record First Quarter Earnings and Royalty Income
9. British Royal highlights anesthesia crisis in the developing world
10. Hoag Memorial Hospital Presbyterian Selects Allscripts for Electronic Health Record Subsidy Program
11. Hill-Rom Announces Agreement With Tri-anim to Enhance Distribution Channels for The Vest(R) System in U.S. Hospitals & Long-Term Care Facilities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize each ... Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into hand ... select a ProHand generator and drag it above media or text in the Final ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
Breaking Medicine Technology: